Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katelyn McCormack

Nurse Practitioner, Adult Health Amherst, NY Nurse Practitioner

NPI 1184889057 CMS profile 10625445

3980 Sheridan Dr, Suite 200, Amherst, NY 14226

Open in the dashboard

General payments

$130,873

1,575 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$70,225 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Katelyn McCormack of Amherst, NY is reported in the CMS Open Payments database as having received $130,873 across 1,575 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $70,225 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,558 319
2024 General $29,463 283
2023 General $25,700 298
2022 General $29,931 389
2021 General $14,220 286

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katelyn McCormack
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Katelyn McCormack were reported at $31,558. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Katelyn McCormack Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $14,220 $138 $43–$438 $132
2022 $29,931 $165 $54–$494 $149
2023 $25,700 $178 $61–$549 $160
2024 $29,463 $186 $62–$575 $164
2025 $31,558 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. EMD Serono, Inc. $43,915 107 payments
  2. Biogen, Inc. $23,645 231 payments
  3. Genzyme Corporation $19,657 49 payments
  4. TG Therapeutics, Inc. $15,948 60 payments
  5. Genentech USA, Inc. $9,692 79 payments
  6. AbbVie, Inc. $2,040 101 payments
  7. Novartis Pharmaceuticals Corporation $1,639 116 payments
  8. Teva Pharmaceuticals USA, Inc. $1,207 79 payments
  9. UCB, Inc. $1,196 66 payments
  10. Neurocrine Biosciences, Inc. $1,003 62 payments
  11. Other $10,931 625 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $88,088 79 payments
  2. Food and Beverage $26,518 1,438 payments
  3. Travel and Lodging $8,883 13 payments
  4. Consulting Fee $6,727 14 payments
  5. Education $658 31 payments
Products named General payments · program years 2021–2025
  1. Mavenclad $27,901 30 payments
  2. BRIUMVI $15,948 60 payments
  3. OCREVUS $9,475 61 payments
  4. VUMERITY Neurology $8,505 128 payments
  5. PLEGRIDY $7,585 82 payments
  6. TYSABRI $5,916 65 payments
  7. VUMERITY Neurology $2,765 18 payments
  8. AVONEX $2,617 50 payments
  9. TECFIDERA $2,278 2 payments
  10. UPLIZNA $904 46 payments
  11. Other $19,156 1,153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

5,567

Median for Nurse Practitioner: 389

Drug cost

$5,332,377

Median for Nurse Practitioner: $21,885

Branded share of claims

28.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mavenclad Cladribine Brand 13 $893,917
Kesimpta Pen Ofatumumab Brand 59 $568,746
Radicava Ors Edaravone Brand 38 $532,850
Rebif Interferon Beta-1a/Albumin Brand 39 $405,288
Rebif Rebidose Interferon Beta-1a/Albumin Brand 40 $395,641
Copaxone Glatiramer Acetate Brand 58 $371,851
Mayzent Siponimod Brand 33 $282,268
Avonex Pen (4 Pack) Interferon Beta-1a Brand 34 $267,641
Glatopa Glatiramer Acetate Brand 73 $189,105
Aubagio Teriflunomide Brand 20 $185,133

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$36,077

Medicare's payments for the services billed

Medicare patients

199

Average age 66

Services billed

591

132 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 51%
Depression 42%
Diabetes 25%
Chronic kidney disease 25%
Ischemic heart disease 22%
Osteoporosis 22%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
$8,703 — —
Mavenclad
$5,325 13 —
VUMERITY
$2,387 — —
TYSABRI
$819 17 —
BOTOX
$331 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

1,575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record